DEA Boosts Psychedelic Production Quotas For 2027 While Previewing Separate Marijuana Proposal Under Rescheduling

The DEA's 2027 marijuana production quotas will stay at 2026 levels for cannabis left in Schedule I, according to a draft Federal Register notice. The agency wants far more MDMA and ibogaine made for research, plus modest increases for psilocybin and psilocyn. A separate notice will cover rescheduled Schedule III marijuana.
Why it matters: Holding Schedule I marijuana quotas flat means research supply isn't growing, while the real change comes later. Medical cannabis moved to Schedule III still has no federal production figures, and DEA is still registering handlers and gathering data. Patients and buyers should read this as a placeholder: the numbers that matter for rescheduled products are still to come.
Reporting by Marijuana Moment. Read the full story at Marijuana Moment.
See how